Advertisement

Indian Journal of Gastroenterology

, Volume 37, Issue 3, pp 196–201 | Cite as

Comparative study of tinidazole versus metronidazole in treatment of amebic liver abscess: A randomized control trial

  • Sudhakar Pandey
  • Gaurav Kumar Gupta
  • Shashank J. Wanjari
  • Sandeep Nijhawan
Original Article
  • 110 Downloads

Abstract

Background

Metronidazole is a drug of choice for amebic liver abscess (ALA), but has long course and significant side effects. Thus, drugs like tinidazole with a better tolerability record need evaluation.

Methods

We conducted a randomized controlled trial at the Department of Gastroenterology, SMS Hospital, Jaipur, India. One hundred and fifty admitted patients were randomized into two treatment groups, metronidazole (group M, n = 75) and tinidazole (group T, n = 75). Patients were observed for clinical response, laboratory parameters, imaging, and side effects. Early clinical response (ECR) was defined as the absence of fever and abdominal pain within 72 h of treatment. Symptomatic clinical response (SCR) was defined as the absence of fever and abdominal pain irrespective of duration of treatment required. Follow up was done at 1, 3, and 6 months.

Results

ECR was 62.3% in group T vs. 37.7% in group M (p = 0.02). SCR was shorter in group T than group M (3.29 ± 1.61 days vs. 5.67 ± 2.93, p ≤ 0.001). Mean residual volume at the end of 1 month was lower in group T (130.7 ± 108.1 vs. 184.7 ± 143.3 mL, p = 0.01) and no significant difference was seen at 3 and 6 months. Tinidazole was better tolerated with fewer side effects. Low socioeconomic status, baseline abscess volume > 500 mL, hypoalbuminemia, pleural effusion, and history of ethanol use were associated with a late clinical response on univariate analysis of which low socioeconomic status was the only associated factor.

Conclusion

Tinidazole, as compared to metronidazole, has early clinical response, shorter treatment course, favorable rate of recovery, and high tolerability; thus, tinidazole can be preferred over metronidazole in ALA.

Keywords

Amebic liver abscess Clinical response Metronidazole Side effects Tinidazole 

Notes

Compliance with ethical standards

Conflict of interest

SP, GKG, SJW, and SN declare that they have no conflict of interest.

Ethics statement

The study was performed in a manner to conform with the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com. The study protocol was approved by the institutional review board and ethics committee.

References

  1. 1.
    Rajagopalan S, Langer V. Symposium hepatic abscesses. Med J Armed Forces India. 2012;68:271–5.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sharma MP, Ahuja V. Amoebic liver abscess. JIACM. 2003;4:107–11.Google Scholar
  3. 3.
    Monro AM. Blood levels of chemotherapeutic drugs and the pharmacokinetics of tinidazole and metronidazole. Curr Med Res Opin. 1974;2:130–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Mathur SN, Itigi A, Knshnaveni, Rai V. Tinidazole and metronidazole in the treatment of amoebic liver abscess. J Int Med Res. 1973;1:429–33.CrossRefGoogle Scholar
  5. 5.
    Siddiqui MNA, Ahad MA, Ekram ARMS, Islam QT, Hoque MA, Masum QAAI. Clinico-pathological profile of liver abscess in a teaching hospital. TAJ. 2008;21:44–9.Google Scholar
  6. 6.
    Stanley SL Jr. Amoebiasis. Lancet. 2003;361:1025–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Li E, Stanley SL Jr. Amebiasis. Gastroenterol Clin N Am. 1996;25:471–92.CrossRefGoogle Scholar
  8. 8.
    Chan RT, Friedman LS. Amebic liver abscess. In: Feldman M, Friedman LS, Brandt LJ, Eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 8th ed. Philadelphia: Saunders; 2006. p. 1749–53.Google Scholar
  9. 9.
    Dias Granado’s CA, Duffus WA, Duffin S, Albrecht H. Parasitic diseases of the liver. In: David Zakim D, Boyer TD, Eds. Hepatology: A Textbook of Liver Disease. 4th ed. Philadelphia: Saunders; 2003. p. 1073–82.Google Scholar
  10. 10.
    Seeto RK, Rockey D. Amebic liver abscess: epidemiology, clinical features, and outcome. West J Med. 1999;170:104–9.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Sharma MP, Ahuja V. Amoebic liver abscess: clinician’s perspective. Bombay Hosp J. 1997;39:615–9.Google Scholar
  12. 12.
    Bakshi JS, Ghaira JN, Nanivedekar AS. How does tinidazole compare with metronidazole? A summary report of Indian trials in amoebiasis and giardiasis. Drugs. 1978;15 Suppl 1:33–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Scragg JN, Proctor EM. Tinidazole in treatment of amoebic liver abscess in children. Arch Dis Child. 1977;52:408–10.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hatchuel W. Tinidazole for the treatment of amoebic liver abscess. S Afr Med J. 1975;49:1879–81.PubMedGoogle Scholar
  15. 15.
    Sharma MP, Dasarathy S, Sushma S, Verma N. Long term follow-up of amebic liver abscess: clinical and ultrasound patterns of resolution. Trop Gastroenterol. 1995;16:24–8.PubMedGoogle Scholar
  16. 16.
    Sheen IS, Chien CS, Lin DY, Liaw YF. Resolution of liver abscesses: comparison of pyogenic and amebic liver abscesses. Am J Trop Med Hyg. 1989;40:384–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Sharma MP, Dasarathy S, Verma N, Sushma S, Shukla DK. Prognostic markers in amebic liver abscess: a prospective study. Am J Gastroenterol. 1996;91:2584–8.PubMedGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2018

Authors and Affiliations

  • Sudhakar Pandey
    • 1
  • Gaurav Kumar Gupta
    • 1
  • Shashank J. Wanjari
    • 1
  • Sandeep Nijhawan
    • 1
  1. 1.Department of GastroenterologySawai Man Singh, Medical CollegeJaipurIndia

Personalised recommendations